{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:54:18Z","timestamp":1761630858560,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.seizure.2019.03.020","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T12:48:00Z","timestamp":1553777280000},"page":"20-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Intravenous use of valproic acid in status epilepticus is associated with high risk of hyperammonemia"],"prefix":"10.1016","volume":"69","author":[{"given":"Jonas","family":"Lind","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Nordlund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2019.03.020_bib0005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1212\/WNL.58.1.139","article-title":"Predictors of functional disability and mortality after status epilepticus","volume":"58","author":"Claassen","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2019.03.020_bib0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12028-012-9695-z","article-title":"Neurocritical care society status epilepticus guideline writing, C. Guidelines for the evaluation and management of status epilepticus","volume":"17","author":"Brophy","year":"2012","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.seizure.2019.03.020_bib0015","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1056\/NEJM199809173391202","article-title":"A comparison of four treatments for generalized convulsive status epilepticus","volume":"339","author":"Treiman","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2019.03.020_bib0020","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1528-1157.2002.25001.x","article-title":"Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy","volume":"43","author":"Vossler","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2019.03.020_bib0025","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s40263-014-0167-1","article-title":"Efficacy and safety of intravenous valproate for status epilepticus: a systematic review","volume":"28","author":"Trinka","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2019.03.020_bib0030","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1212\/01.wnl.0000224880.35053.26","article-title":"Sodium valproate vs phenytoin in status epilepticus: a pilot study","volume":"67","author":"Misra","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2019.03.020_bib0035","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.seizure.2007.04.012","article-title":"Randomized study of intravenous valproate and phenytoin in status epilepticus","volume":"16","author":"Agarwal","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2019.03.020_bib0040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.seizure.2013.12.007","article-title":"The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies","volume":"23","author":"Yasiry","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2019.03.020_bib0045","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","article-title":"Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug","volume":"15","author":"Tomson","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2019.03.020_bib0050","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2019.03.020_bib0055","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1212\/WNL.31.9.1173","article-title":"Valproic acid and secondary hyperammonemia","volume":"31","author":"Rawat","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2019.03.020_bib0060","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1212\/WNL.32.2.206","article-title":"Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction","volume":"32","author":"Zaret","year":"1982","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2019.03.020_bib0065","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1212\/WNL.54.1.230","article-title":"Valproate-induced hyperammonemic encephalopathy in the presence of topiramate","volume":"54","author":"Hamer","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2019.03.020_bib0070","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1553-2712.2001.tb01102.x","article-title":"Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy","volume":"8","author":"Barrueto","year":"2001","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.seizure.2019.03.020_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2006.00655.x","article-title":"Valproate-induced hyperammonemic encephalopathy","volume":"114","author":"Segura-Bruna","year":"2006","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2019.03.020_bib0080","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1600-0404.2006.00793.x","article-title":"Non-convulsive status epilepticus secondary to valproic acid-induced hyperammonemic encephalopathy","volume":"116","author":"Velioglu","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2019.03.020_bib0085","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus\u2014report of the ILAE Task Force on Classification of Status Epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2019.03.020_bib0090","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/WNL.65.3.500-a","article-title":"Efficacy of rapid IV administration of valproic acid for status epilepticus","volume":"65","author":"Rossetti","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2019.03.020_bib0095","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eplepsyres.2009.02.012","article-title":"Hyperammonemia following intravenous valproate loading","volume":"85","author":"DeWolfe","year":"2009","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2019.03.020_bib0100","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/217269","article-title":"Hyperammonemia associated with valproic acid concentrations","volume":"2014","author":"Vazquez","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.seizure.2019.03.020_bib0105","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0920-1211(99)00005-4","article-title":"Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients","volume":"35","author":"Venkataraman","year":"1999","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2019.03.020_bib0110","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1528-1167.2007.00989.x","article-title":"Safety of rapid intravenous loading of valproate","volume":"48","author":"Limdi","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2019.03.020_bib0115","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00134-005-2695-0","article-title":"Pharmacokinetic interaction between valproic acid and meropenem","volume":"31","author":"Clause","year":"2005","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.seizure.2019.03.020_bib0120","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.2215\/CJN.01320216","article-title":"The role of RRT in hyperammonemic patients","volume":"11","author":"Gupta","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.seizure.2019.03.020_bib0125","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.yebeh.2015.04.010","article-title":"Preliminary results of the global audit of treatment of refractory status epilepticus","volume":"49","author":"Ferlisi","year":"2015","journal-title":"Epilepsy Behav"},{"issue":"Suppl. 6","key":"10.1016\/j.seizure.2019.03.020_bib0130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/epi.12288","article-title":"The established status epilepticus trial 2013","volume":"54","author":"Bleck","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2019.03.020_bib0135","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1093\/brain\/awr215","article-title":"The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol","volume":"134","author":"Shorvon","year":"2011","journal-title":"Brain"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131118306976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131118306976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:52:24Z","timestamp":1761011544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131118306976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":27,"alternative-id":["S1059131118306976"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2019.03.020","relation":{},"ISSN":["1059-1311"],"issn-type":[{"type":"print","value":"1059-1311"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous use of valproic acid in status epilepticus is associated with high risk of hyperammonemia","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2019.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}